Captrust Financial Advisors Sells 6,396 Shares of Certara, Inc. (NASDAQ:CERT)

Captrust Financial Advisors cut its position in shares of Certara, Inc. (NASDAQ:CERT) by 29.4% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,370 shares of the company’s stock after selling 6,396 shares during the period. Captrust Financial Advisors’ holdings in Certara were worth $180,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of CERT. Blue Trust Inc. acquired a new stake in Certara in the 2nd quarter valued at $26,000. Innealta Capital LLC acquired a new position in Certara in the second quarter worth $36,000. KBC Group NV boosted its stake in Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares in the last quarter. Intech Investment Management LLC acquired a new position in Certara in the second quarter worth $152,000. Finally, Algert Global LLC acquired a new position in Certara in the second quarter worth $156,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Insider Activity at Certara

In other Certara news, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at $552,503.73. This represents a 9.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.39% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th. Barclays dropped their target price on Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, November 7th. Finally, Robert W. Baird dropped their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $15.92.

Certara Trading Up 0.9 %

NASDAQ CERT opened at $11.57 on Tuesday. The stock has a 50-day simple moving average of $10.85 and a 200 day simple moving average of $12.57. The company has a market capitalization of $1.86 billion, a PE ratio of -57.85, a P/E/G ratio of 5.86 and a beta of 1.53. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm’s revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 earnings per share. Research analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.